Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 4
2018 7
2019 4
2020 3
2021 10
2022 14
2023 5
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
The Emerging Landscape of Immune Cell Therapies.
Weber EW, Maus MV, Mackall CL. Weber EW, et al. Cell. 2020 Apr 2;181(1):46-62. doi: 10.1016/j.cell.2020.03.001. Cell. 2020. PMID: 32243795 Free PMC article. Review.
Tuning the Antigen Density Requirement for CAR T-cell Activity.
Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, Myklebust JH, Kadapakkam M, Weber EW, Tousley AM, Richards RM, Heitzeneder S, Nguyen SM, Wiebking V, Theruvath J, Lynn RC, Xu P, Dunn AR, Vale RD, Mackall CL. Majzner RG, et al. Cancer Discov. 2020 May;10(5):702-723. doi: 10.1158/2159-8290.CD-19-0945. Epub 2020 Mar 19. Cancer Discov. 2020. PMID: 32193224 Free PMC article.
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G, Garrigan E, Xu P, Huang J, Salzer B, Delaidelli A, Raman S, Cui H, Martinez B, Bornheimer SJ, Sahaf B, Alag A, Fetahu IS, Hasselblatt M, Parker KR, Anbunathan H, Hwang J, Huang M, Sakamoto K, Lacayo NJ, Klysz DD, Theruvath J, Vilches-Moure JG, Satpathy AT, Chang HY, Lehner M, Taschner-Mandl S, Julien JP, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL. Heitzeneder S, et al. Cancer Cell. 2022 Jan 10;40(1):53-69.e9. doi: 10.1016/j.ccell.2021.12.005. Epub 2021 Dec 30. Cancer Cell. 2022. PMID: 34971569 Free PMC article.
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
Theruvath J, Menard M, Smith BAH, Linde MH, Coles GL, Dalton GN, Wu W, Kiru L, Delaidelli A, Sotillo E, Silberstein JL, Geraghty AC, Banuelos A, Radosevich MT, Dhingra S, Heitzeneder S, Tousley A, Lattin J, Xu P, Huang J, Nasholm N, He A, Kuo TC, Sangalang ERB, Pons J, Barkal A, Brewer RE, Marjon KD, Vilches-Moure JG, Marshall PL, Fernandes R, Monje M, Cochran JR, Sorensen PH, Daldrup-Link HE, Weissman IL, Sage J, Majeti R, Bertozzi CR, Weiss WA, Mackall CL, Majzner RG. Theruvath J, et al. Nat Med. 2022 Feb;28(2):333-344. doi: 10.1038/s41591-021-01625-x. Epub 2022 Jan 13. Nat Med. 2022. PMID: 35027753 Free PMC article.
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP. Goldsmith KC, et al. Nat Med. 2023 May;29(5):1092-1102. doi: 10.1038/s41591-023-02297-5. Epub 2023 Apr 3. Nat Med. 2023. PMID: 37012551 Free PMC article. Clinical Trial.
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma.
Durbin AD, Wang T, Wimalasena VK, Zimmerman MW, Li D, Dharia NV, Mariani L, Shendy NAM, Nance S, Patel AG, Shao Y, Mundada M, Maxham L, Park PMC, Sigua LH, Morita K, Conway AS, Robichaud AL, Perez-Atayde AR, Bikowitz MJ, Quinn TR, Wiest O, Easton J, Schönbrunn E, Bulyk ML, Abraham BJ, Stegmaier K, Look AT, Qi J. Durbin AD, et al. Cancer Discov. 2022 Mar 1;12(3):730-751. doi: 10.1158/2159-8290.CD-21-0385. Cancer Discov. 2022. PMID: 34772733 Free PMC article.
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
Mabe NW, Huang M, Dalton GN, Alexe G, Schaefer DA, Geraghty AC, Robichaud AL, Conway AS, Khalid D, Mader MM, Belk JA, Ross KN, Sheffer M, Linde MH, Ly N, Yao W, Rotiroti MC, Smith BAH, Wernig M, Bertozzi CR, Monje M, Mitsiades CS, Majeti R, Satpathy AT, Stegmaier K, Majzner RG. Mabe NW, et al. Nat Cancer. 2022 Aug;3(8):976-993. doi: 10.1038/s43018-022-00405-x. Epub 2022 Jul 11. Nat Cancer. 2022. PMID: 35817829 Free PMC article.
Inhibiting 4EBP1 in Glioblastoma.
Fan QW, Nicolaides TP, Weiss WA. Fan QW, et al. Clin Cancer Res. 2018 Jan 1;24(1):14-21. doi: 10.1158/1078-0432.CCR-17-0042. Epub 2017 Jul 10. Clin Cancer Res. 2018. PMID: 28696243 Free PMC article. Review.
46 results